Triple
T36600545
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | APHINITY |
E902901
|
entity |
| Predicate | HER2StatusInclusion |
P186064
|
FINISHED |
| Object | HER2-positive |
—
|
LITERAL FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: HER2-positive | Statement: [APHINITY, HER2StatusInclusion, HER2-positive]
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: HER2StatusInclusion Context triple: [APHINITY, HER2StatusInclusion, HER2-positive]
-
A.
hormoneReceptorStatusInclusion
Indicates that inclusion in a group, study, or category is determined based on the hormone receptor status of the relevant biological sample or subject.
-
B.
isTumorAgnostic
Indicates that a treatment, biomarker, or effect applies across multiple tumor types regardless of the cancer’s tissue or organ of origin.
-
C.
hasPrognosticFactor
Indicates that something serves as a factor influencing or predicting the likely outcome or course of a condition, event, or situation.
-
D.
usedAsBiomarkerFor
Indicates that one entity serves as a biomarker for another entity, typically signaling the presence, progression, or risk of a specific condition or biological state.
-
E.
Ki67Significance
Indicates the relationship between Ki-67 expression levels and their interpreted significance for cell proliferation, tumor aggressiveness, or clinical outcome.
- F. None of above. chosen
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f76e66b7b88190848f7a3e1188915f |
completed | May 3, 2026, 3:48 p.m. |
| NER | Named-entity recognition | batch_69f7c83f5960819089610ed39c839678 |
completed | May 3, 2026, 10:12 p.m. |
| PD | Predicate disambiguation | batch_69f7c477a4d481908f52e55b6688f60c |
completed | May 3, 2026, 9:56 p.m. |
| PDg | Predicate description generation | batch_69f7c776b4088190bef550c869da530d |
completed | May 3, 2026, 10:08 p.m. |
Created at: May 3, 2026, 4:11 p.m.